Kinarus AG
Ticker: KNRS Exchange: SIX
Kinarus AG is a clinical-stage pharmaceutical company focused on bringing novel treatments to patients suffering from viral, respiratory, and ophthalmic diseases. Kinarus’s unique and innovative combinatorial therapeutic candidate has broad potential to transform numerous therapeutic areas.

AGM and recent financing

Kinarus’ Therapeutics AG held its AGM on June 28th. Shareholders approved all proposals, re-electing the current members of the Board of Directors for another term. Kinarus also recently received a subordinated CHF1.5m convertible loan investment by CDIM, an investment group in China. This equity-backed financing is intended to support Kinarus with the intention of entering negotiation for regional licenses for KIN001.

In addition, the US FDA and other countries continue to facilitate the development of drugs to treat and prevent COVID-19. The KINFAST phase 2 trial of KIN001 in outpatients remains open to recruitment in Switzerland and Germany. Kinarus appears to have most of the bases covered in this difficult biotech environment.

While we await the completion of the CDIM and subsequent transactions, our fair value for Kinarus remains at CHF 93m, or CHF 0.093 per share.

Download as a PDF file
26810392321 - kinarus-ag
Return to Kinarus AG

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates